Raltitrexed (Tomudex(TM)) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: Preliminary results from phase I clinical trials

European Journal of Cancer

Volumn 35, Issue SUPPL. 1, 1999, Pages S9-

  Schwartz, G K ^a   Harstrick, A ^b   Gonzalez Baron M ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Raltitrexed; Tegafur uracil

Indexed keywords

FLUOROURACIL; RALTITREXED; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADULT; AGED; ARTICLE; COLORECTAL TUMOR; DOSE RESPONSE; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; THIOPHENES; TREATMENT OUTCOME;

EID: 0033103659     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(99)00042-8     Document Type: Conference Paper

References (21)

1. Cunningham D. Mature results from three large controlled studies with raltitrexed (`Tomudex'). Br. J. Cancer. 77(Suppl. 2):1998;15-21.
2. Kemeny N., Lokich J.J., Anderson N., Ahlgren J.D. Recent advances in the treatment of advanced colorectal cancer. Cancer. 71:1993;9-18.
3. Moertel C.G. Chemotherapy for colorectal cancer. N. Engl. J. Med. 330:1994;1136-1142.
4. Zalcberg J.R., Cunningham D., Van Cutsem E.et al. ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J. Clin. Oncol. 14:1996;716-721.
5. Gunasekara N.S., Faulds D. Raltitrexed: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs. 55:1998;423-435.
6. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinetics. 16:1989;215-237.
7. Cocconi G., Cunningham D., Van Cutsem E.et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J. Clin. Oncol. 16:1998;2943-2952.
8. Lokich J.J., Ahlgren J.D., Gullo J.J., Philips J.A., Fryer J.G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J. Clin. Oncol. 7:1989;425-432.
9. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16, 301-308.
10. Aschele C., Sobrero A., Faderan M.A., Bertino J.R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 52:1992;1855-1864.
11. Longo G.S.A., Izzo J., Chang Y.M.et al. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. Clin. Cancer Res. 4:1998;469-473.
12. Harstrick A., Schleucher N., Gonzales A.et al. Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidylate synthase inhibitor `Tomudex' (D1694). Eur. J. Cancer. 31A(Suppl. 5):1995;S30.
13. Van der Wilt CL, Pinedo HM, Kuiper CM, Smid K, Peters GJ. Biochemical basis for the combined antiproliferative effect of AG337 or ZD1694 and 5-fluorouracil. Proc Am Assoc Cancer Res 1995, 36, 379 (A2260).
14. Yan JM, Lu ZH, Shao LN, Diasio RB. The effect of `Tomudex' on dihydropyrimidine dehydrogenase activity. Proc Am Assoc Cancer Res 1997, 38 (abstract 4133).
15. Schwartz GK, Bertino JL, Kemeny N, et al. Interim results of a phase I trial suggest that `Tomudex' (raltitrexed) may act synergistically with 5-FU in patients with advanced colorectal cancer (CRC). Ann Oncol 1998, 9(Suppl. 4), 36 (abstract 171P).
16. Harstrick A, Mayer S, Hilger R, et al. Combination therapy with infusional 5-FU and `Tomudex' for patients (pts) with advanced colorectal cancer - A phase I study. Ann Oncol 1998, 9(Suppl. 4), 35 (abstract 170P).
17. Sorensen JM, Jordan E, Grem JL, et al. Phase I trial of ZD 1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol 1994, 5(Suppl. 5), 132 (A241).
18. Poon M.A., O'Connell M.J., Wieand H.S.et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol. 9:1991;1967-1972.
19. Ardalan B., Chua L., Tian E.M.et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J. Clin. Oncol. 9:1991;625-630.
20. Takiuchi H., Ajani J.A. Uracil-tegafur in gastric carcinoma: A comprehensive review. J. Clin. Oncol. 16:1998;2877-2885.
21. Grohn P., Heinonen E., Kumpulainen E.et al. Oral carmofur in advanced gastrointestinal cancer. Am. J. Clin. Oncol. 13:1990;477-479.